ERBB2 and breast carcinoma: A number of studies focussed on investigating the treatment of patients with ER+/HER2-low (HER2 IHC 1+/2+, FISH negative) breast cancer, which is not effectively treated with first-generation anti-HER2 agents, such as trastuzumab.